MCID: INT068
MIFTS: 53

Intestinal Disease

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Intestinal Disease

MalaCards integrated aliases for Intestinal Disease:

Name: Intestinal Disease 12 15 17
Intestinal Diseases 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5295
ICD9CM 34 569.9
MeSH 43 D007410
NCIt 49 C26801
SNOMED-CT 67 85919009
ICD10 32 K63.9
UMLS 71 C0021831

Summaries for Intestinal Disease

Disease Ontology : 12 A gastrointestinal system disease that is located in the intestine.

MalaCards based summary : Intestinal Disease, also known as intestinal diseases, is related to inflammatory bowel disease and short bowel syndrome, and has symptoms including constipation, diarrhea and signs and symptoms, digestive. An important gene associated with Intestinal Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Tocopherol and Copper have been mentioned in the context of this disorder. Affiliated tissues include intestine, small intestine and colon.

Wikipedia : 74 The gastrointestinal tract (digestive tract, alimentary canal, digestion tract, GI tract, GIT) is an... more...

Related Diseases for Intestinal Disease

Diseases in the Intestinal Disease family:

Chronic Intestinal Failure Congenital Intestinal Disease Due to an Enzymatic Defect
Intestinal Disease Due to Fat Malabsorption Intestinal Disease Due to Vitamin Absorption Anomaly
Rare Intestinal Disease

Diseases related to Intestinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 542)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 33.3 TP53 TFF3 MIR21 MIR155 ICOSLG GHRL
2 short bowel syndrome 33.2 GHRL GCG AOC1
3 colonic disease 33.0 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
4 celiac disease 1 31.6 ICOSLG H2AC18 GHRL GCG CCR6
5 gastrointestinal system disease 31.4 MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR145
6 b-cell lymphoma 31.2 TP53 MIR21 MIR17 MIR155 BCL6
7 peptic ulcer disease 31.2 TP53 H2AC18 GHRL DEFB4A
8 colitis 31.1 UCN TFF3 ICOSLG CCR6
9 gastritis 31.1 TP53 GHRL DEFB4A CCR6
10 lymphoma, mucosa-associated lymphoid type 31.0 TP53 SDC1 ICOSLG CCR6 BCL6
11 diffuse large b-cell lymphoma 30.8 TP53 SDC1 MIR21 MIR199A1 MIR17 MIR155
12 marginal zone b-cell lymphoma 30.7 SDC1 CCR6 BCL6
13 intestinal benign neoplasm 30.6 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR145
14 lymphoma, hodgkin, classic 30.6 MIR21 MIR155 ICOSLG CCR6 BCL6
15 eye disease 30.6 TP53 MIR21 MIR199A1 MIR196A1 MIR17 ICOSLG
16 kidney cancer 30.5 TP53 MIR21 MIR199A1 MIR17 ICOSLG H2AC18
17 pulmonary disease, chronic obstructive 30.5 MIR21 MIR199A1 MIR17 ICOSLG H2AC18 CCR6
18 ovarian disease 30.5 TP53 MIR21 MIR199A1 MIR17 MIR145 MIR143
19 lymphoma, non-hodgkin, familial 30.5 TP53 SDC1 MIR21 MIR199A1 MIR196A1 MIR17
20 colorectal adenoma 30.5 TP53 MIR21 MIR17 APC
21 prostate disease 30.5 MIR21 MIR199A1 MIR196A1 MIR17 MIR145 MIR143
22 allergic hypersensitivity disease 30.5 ICOSLG H2AC18 CCR6 AOC1
23 colorectal cancer 30.5 TP53 TFF3 MIR21 MIR199A1 MIR196A1 MIR17
24 systemic scleroderma 30.5 MIR21 ICOSLG H2AC18 CCR6
25 coccidiosis 30.5 ICOSLG H2AC18 CCR6
26 pancreatic cancer 30.5 TP53 MIR21 MIR199A1 MIR196A1 MIR17 MIR155
27 cholangitis, primary sclerosing 30.5 MIR199A1 ICOSLG CCR6
28 esophageal cancer 30.5 TP53 MIR21 MIR199A1 MIR196A1 MIR155 MIR145
29 non-alcoholic fatty liver disease 30.5 MIR21 MIR199A1 MIR17 MIR155 GCG
30 endometriosis 30.4 TP53 MIR199A1 MIR145 MIR143
31 bone disease 30.2 SDC1 ICOSLG H2AC18 CCR6
32 rare intestinal disease 12.2
33 genetic intestinal disease 12.1
34 genetic intestinal disease due to fat malabsorption 12.1
35 congenital intestinal disease due to an enzymatic defect 12.1
36 intestinal disease due to fat malabsorption 12.1
37 intestinal disease due to vitamin absorption anomaly 12.1
38 alpha-heavy chain disease 11.9
39 alpha chain disease 11.8
40 crohn's disease 11.5
41 protozoal dysentery 11.4
42 cystoisosporiasis 11.4
43 irritable bowel syndrome 11.2
44 diverticulitis 11.2
45 blind loop syndrome 11.2
46 familial adenomatous polyposis 11.2
47 stomach disease 10.9 TP53 MIR196A1 ICOSLG H2AC18 GHRL GCG
48 plasma cell neoplasm 10.9 TP53 SDC1 ICOSLG BCL6
49 mature b-cell neoplasm 10.9 TP53 SDC1 MIR199A1 MIR196A1 MIR17 MIR155
50 vaginal disease 10.9 TP53 H2AC18 DEFB4A CCR6

Comorbidity relations with Intestinal Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Intestinal Obstruction
Paralytic Ileus

Graphical network of the top 20 diseases related to Intestinal Disease:



Diseases related to Intestinal Disease

Symptoms & Phenotypes for Intestinal Disease

UMLS symptoms related to Intestinal Disease:


constipation, diarrhea, signs and symptoms, digestive, anal or rectal pain

Drugs & Therapeutics for Intestinal Disease

Drugs for Intestinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 346)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
2
Copper Approved, Investigational Phase 4 7440-50-8 27099
3
Prucalopride Approved Phase 4 179474-81-8
4
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
5
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
6
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
7
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
8
Lactulose Approved Phase 4 4618-18-2 11333
9
Simethicone Approved Phase 4 8050-81-5
10
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
11
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
12
Ibuprofen Approved Phase 4 15687-27-1 3672
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
Sodium citrate Approved, Investigational Phase 4 68-04-2
15
Fidaxomicin Approved Phase 4 873857-62-6
16
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
17
Mebendazole Approved, Vet_approved Phase 4 31431-39-7 4030
18
Piperazine Approved, Vet_approved Phase 4 110-85-0 4837
19
Ondansetron Approved Phase 4 99614-02-5 4595
20
Adalimumab Approved Phase 4 331731-18-1 16219006
21
leucovorin Approved Phase 4 58-05-9 6006 143
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Racepinephrine Approved Phase 4 329-65-7 838
26
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
27 Vedolizumab Approved Phase 4 943609-66-3
28
Infliximab Approved Phase 4 170277-31-3
29
Certolizumab pegol Approved Phase 4 428863-50-7
30
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
31
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
35
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
36 Tocotrienol Investigational Phase 4 6829-55-6
37 Antioxidants Phase 4
38 Cyclooxygenase Inhibitors Phase 4
39 Fibrinolytic Agents Phase 4
40 Platelet Aggregation Inhibitors Phase 4
41 Antipyretics Phase 4
42 Hepcidins Phase 4
43 Copper Supplement Phase 4
44 Tocopherols Phase 4
45 Tocotrienols Phase 4
46 Serotonin Receptor Agonists Phase 4
47 Iron Supplement Phase 4
48 Ferric Oxide, Saccharated Phase 4
49 Anthelmintics Phase 4
50 Antacids Phase 4

Interventional clinical trials:

(show top 50) (show all 732)
# Name Status NCT ID Phase Drugs
1 Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section Unknown status NCT02571881 Phase 4 Oxycodone;oxycodone-naloxone
2 Prospective Trial Comparing Single-Operator and Dual-Operator Double-balloon Endoscopy in Patients With Small-Bowel Disorders Unknown status NCT01184690 Phase 4
3 Prospective Trial Comparing Push-and-Pull Enteroscopy With the Single- and Double-Balloon Techniques in Patients With Obscure Small-Bowel Bleeding Unknown status NCT01176864 Phase 4
4 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Unknown status NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
5 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
6 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
7 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
8 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
9 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
10 Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth Completed NCT01748929 Phase 4 Albendazole;Placebo
11 Effect of Intestinal Helminths on Gut Microflora Completed NCT01192802 Phase 4 albendazole;albendazole;albendazole
12 Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery Completed NCT02573922 Phase 4 oxycodone-naloxone;Oxycodone
13 The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single−Blind, Randomized, Multi-center Study Completed NCT02486536 Phase 4 polyethylene glycol
14 Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD) Completed NCT00640809 Phase 4 Celecoxib;Ibuprofen plus Omeprazole
15 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
16 Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program. Completed NCT01934088 Phase 4 Propofol;Midazolam;Fentanyl
17 Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
18 Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients Completed NCT02461758 Phase 4
19 Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) Completed NCT02437591 Phase 4 fidaxomicin
20 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
21 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
22 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial Completed NCT02010762 Phase 4 Vitamin D;Placebo
23 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
24 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness Completed NCT02162862 Phase 4 bupropion-SR
25 Improving Early Childhood Growth and Development in Resource-poor LMICs by Incorporating Deworming in Integrated Child Health Care Completed NCT01314937 Phase 4 Mebendazole
26 Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission Completed NCT02453776 Phase 4 PRECISION dosing Infliximab
27 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
28 Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea Completed NCT03833999 Phase 4 Ondansetron 8mg;Lactulose;Placebo oral capsule
29 A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy Completed NCT02334631 Phase 4 High Volume Simethicone;Standard Volume Simethicone
30 A Randomised Controlled Trial Comparing the Efficacy of Intravenous Iron Sucrose and Oral Iron Sulfate in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
31 Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies Recruiting NCT03866538 Phase 4 Withdrawal of Oral Budesonide
32 Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases Recruiting NCT01793831 Phase 4
33 Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation Recruiting NCT02994836 Phase 4 Anti-TNF discontinuation: Physiological saline solution;Anti-TNF discontinuation: Physiological saline solution
34 Evaluating the Efficacy of Weekly Folic Acid in Pediatric Inflammatory Bowel Disease Patients on Methotrexate Recruiting NCT03860012 Phase 4 Folic Acid
35 Chronotherapy in Inflammatory Bowel Disease Recruiting NCT04304950 Phase 4 Evening Group;Morning Group
36 Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Recruiting NCT03885713 Phase 4
37 Stricture Definition and Treatment (STRIDENT) Drug Therapy Study Active, not recruiting NCT03220841 Phase 4 Adalimumab Injection;Thiopurine
38 A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial Active, not recruiting NCT03723447 Phase 4 Liposomal bupivacaine;Bupivacaine/epinephrine/dexamethasone
39 The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial Enrolling by invitation NCT02704624 Phase 4
40 A Pilot Study Evaluating Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Suspended NCT03798691 Phase 4
41 Pilot Study of the Role of PET-CT for Diagnosis and Assessment of Therapeutic Efficacy in Inflammatory Bowel Disease Terminated NCT00205062 Phase 4
42 A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease Terminated NCT02566889 Phase 4 Infliximab
43 Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine Terminated NCT01696942 Phase 4 Cimzia;Mesalamine
44 Thiopurine Induced Pancreatitis in IBD Patients Withdrawn NCT02281799 Phase 4 Azathioprine
45 Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study Unknown status NCT01496053 Phase 2, Phase 3
46 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation Unknown status NCT01863407 Phase 3 DAM;Normal Saline
47 Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Unknown status NCT02044952 Phase 2, Phase 3 Mesalazine, Tripterygium glycosides
48 Efficacy of Fecal Microbiota Transplantation for Refractory Inflammatory Bowel Disease Unknown status NCT02575040 Phase 3
49 A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Oligosaccharide (Monofer®) Administered by Infusions or Repeated Bolus Injections in Comparison With Oral Iron Sulphate in Inflammatory Bowel Disease Subjects With Iron Deficiency Anaemia Completed NCT01017614 Phase 3 Monofer;Iron Sulphate
50 A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain Completed NCT01929044 Phase 3 654-II (anisodamine);Buscopan® (hyoscine butylbromide)

Search NIH Clinical Center for Intestinal Disease

Cochrane evidence based reviews: intestinal diseases

Genetic Tests for Intestinal Disease

Anatomical Context for Intestinal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Intestinal Disease:

19
Intestine

MalaCards organs/tissues related to Intestinal Disease:

40
Small Intestine, Colon, Testes, Liver, T Cells, Bone, Skin

Publications for Intestinal Disease

Articles related to Intestinal Disease:

(show top 50) (show all 4170)
# Title Authors PMID Year
1
Probiotic potential and safety assessment of Lactobacillus isolated from yaks. 61
32333954 2020
2
Microbial communities modulating brain functioning and behaviors in zebrafish: A mechanistic approach. 61
32418919 2020
3
Analyses of genetics and pathogenesis of Salmonella enterica QH with narrow spectrum of antibiotic resistance isolated from yak. 61
32247035 2020
4
Cutaneous manifestations in inflammatory bowel disease (Review). 61
32508989 2020
5
Immunization of mice against alpha, beta, and epsilon toxins of Clostridium perfringens using recombinant rCpa-b-x expressed by Bacillus subtilis. 61
32447084 2020
6
Cryptosporidium sp. skunk genotype in wild raccoons (Procyon lotor) naturally infected with Baylisascaris procyonis from Central Germany. 61
32574726 2020
7
Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity. 61
32560118 2020
8
Intestinal effect of the probiotic Escherichia coli strain Nissle 1917 and its OMV. 61
32550212 2020
9
Vedolizumab-associated psoriasis: until where does gut selectivity go? 61
32496114 2020
10
Schistosomiasis-from immunopathology to vaccines. 61
32076812 2020
11
Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function? 61
32545596 2020
12
Diagnostic findings and long-term prognosis in children with anemia undergoing GI endoscopies. 61
31917169 2020
13
The Assessment of Fecal Volatile Organic Compounds in Healthy Infants: Electronic Nose Device Predicts Patient Demographics and Microbial Enterotype. 61
32526503 2020
14
Cell death of intestinal epithelial cells in intestinal diseases. 61
32572429 2020
15
Antibodies to Crohn's disease peptide 353 as a diagnostic marker for pediatric Crohn's disease: a prospective multicenter study in Japan. 61
31980893 2020
16
[New challenges for intensive care medicine due to climate change and global warming]. 61
32399720 2020
17
Dual role of Ca2+-activated Cl- channel transmembrane member 16A in lipopolysaccharide-induced intestinal epithelial barrier dysfunction in vitro. 61
32472021 2020
18
Multidisciplinary and Multisociety Practice Guideline on Reprocessing Flexible Gastrointestinal Endoscopes and Endoscopic Accessories. 61
32506894 2020
19
The intestinal injury caused by ischemia-reperfusion is attenuated by amniotic fluid stem cells via the release of tumor necrosis factor-stimulated gene 6 protein. 61
32223023 2020
20
Mucus blocks probiotics but increases penetration of motile pathogens and induces TNF-α and IL-8 secretion. 61
32396232 2020
21
WCE polyp detection based on novel feature descriptor with normalized variance locality-constrained linear coding. 61
32447521 2020
22
Development and application of a LC-MS/MS assay for simultaneous analysis of 25-hydroxyvitamin-D and 3-epi-25-hydroxyvitamin-D metabolites in canine serum. 61
31958632 2020
23
Normative values for circulating intestinal fatty acid binding protein and calprotectin across gestational ages. 61
32456678 2020
24
Protein-elongating mutations in MYH11 are implicated in a dominantly inherited smooth muscle dysmotility syndrome with severe esophageal, gastric, and intestinal disease. 61
31944481 2020
25
Profile analysis reveals endogenous RNAs regulate necrotizing enterocolitis progression. 61
32036223 2020
26
The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. 61
32429454 2020
27
The importance of lactose intolerance in individuals with gastrointestinal symptoms. 61
32482516 2020
28
Intestinal Inflammation Alters the Expression of Hepatic Bile Acid Receptors Causing Liver Impairment. 61
32404746 2020
29
Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment. 61
32393180 2020
30
Impact of air pollution on intestinal redox lipidome and microbiome. 61
31904545 2020
31
Physiological characteristics of Lactobacillus casei strains and their alleviation effects against inflammatory bowel disease. 61
32522964 2020
32
New genotype classification and molecular characterization of canine and feline parvoviruses. 61
32476317 2020
33
Protein-losing enteropathy. 61
32073507 2020
34
Fungal Trans-kingdom Dynamics Linked to Responsiveness to Fecal Microbiota Transplantation (FMT) Therapy in Ulcerative Colitis. 61
32298656 2020
35
Genomic data reveal international lineages of critical priority Escherichia coli harbouring wide resistome in Andean condors (Vultur gryphus Linnaeus, 1758). 61
32335957 2020
36
Anticoccidial and Antioxidant Activities of Moringa oleifera Leaf Extract on Murine Intestinal Eimeriosis. 61
32472400 2020
37
GTS-21 Promotes α7 nAChR to Alleviate Intestinal Ischemia-Reperfusion-Induced Apoptosis and Inflammation of Enterocytes. 61
32417847 2020
38
Cultivation of the Next-Generation Probiotic Akkermansia muciniphila, Methods of Its Safe Delivery to the Intestine, and Factors Contributing to Its Growth In Vivo. 61
32318863 2020
39
Bifidobacterium infantis Relieves Allergic Asthma in Mice by Regulating Th1/Th2. 61
32249275 2020
40
Intestinal microbiota characteristics of mice treated with Folium senna decoction gavage combined with restraint and tail pinch stress. 61
32231961 2020
41
Compare risk factors associated with postoperative infectious complication in Crohn's disease with and without preoperative infliximab therapy: a cohort study. 61
32060607 2020
42
Berberine ameliorates non-steroidal anti-inflammatory drugs-induced intestinal injury by the repair of enteric nervous system. 61
31520444 2020
43
Dietary supplementation of micro-encapsulated sodium butyrate in healthy horses: effect on gut histology and immunohistochemistry parameters. 61
32345290 2020
44
Bone Health, Calcium, Vitamin D Metabolism, and Gastro-Intestinal Diseases. 61
32220592 2020
45
Metagenomic sequencing of clinical samples reveals a single widespread clone of Lawsonia intracellularis responsible for porcine proliferative enteropathy. 61
32238228 2020
46
Functional characterization and subcellular distribution of two recombinant cytosolic HSP70 isoforms from Entamoeba histolytica under normal and stress conditions. 61
32056023 2020
47
Antibacterial activity of cyadox against Clostridium perfringens in broilers and a dosage regimen design based on pharmacokinetic-pharmacodynamic modeling. 61
31962185 2020
48
Bayesian model averaging for the X-chromosome inactivation dilemma in genetic association study. 61
30247537 2020
49
Factors that influence treatment-seeking expectations in response to infectious intestinal disease: Original survey and multinomial regression. 61
31818708 2020
50
Gut dysbacteriosis and intestinal disease: mechanism and treatment. 61
32277534 2020

Variations for Intestinal Disease

Copy number variations for Intestinal Disease from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 37762 1 94500000 107000000 Gain AMY1 Intestinal disease
2 37786 1 94700000 107200000 Loss AMY1 Intestinal disease
3 84156 14 23788159 23802256 Insertion TGM1 Intestinal disease

Expression for Intestinal Disease

Search GEO for disease gene expression data for Intestinal Disease.

Pathways for Intestinal Disease

Pathways related to Intestinal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 TP53 MIR21 MIR199A1 MIR17 MIR155 MIR145
2 10.07 MIR199A1 MIR145

GO Terms for Intestinal Disease

Cellular components related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 TFF3 MIR21 MIR199A1 MIR17 MIR155 MIR143

Biological processes related to Intestinal Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.89 TP53 MIR155 GHRL BCL6
2 negative regulation of gene expression GO:0010629 9.89 UCN TP53 MIR21 MIR17 MIR155
3 negative regulation of apoptotic process GO:0043066 9.88 UCN TP53 MIR21 GHRL GCG BCL6
4 negative regulation of angiogenesis GO:0016525 9.78 MIR21 MIR145 MIR143 GHRL
5 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.74 MIR199A1 MIR196A1 MIR155
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.69 MIR21 MIR199A1 MIR145
7 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.62 MIR17 MIR155
8 positive regulation of connective tissue replacement GO:1905205 9.62 MIR199A1 MIR155
9 positive regulation of histone deacetylation GO:0031065 9.61 TP53 BCL6
10 positive regulation of metalloendopeptidase activity GO:1904685 9.61 MIR21 MIR17
11 angiotensin-activated signaling pathway GO:0038166 9.6 MIR145 MIR143
12 negative regulation of regulatory T cell differentiation GO:0045590 9.58 MIR21 MIR155
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.58 MIR21 MIR17
14 negative regulation of necrotic cell death GO:0060547 9.56 UCN MIR155
15 miRNA mediated inhibition of translation GO:0035278 9.56 MIR21 MIR17 MIR155 MIR145
16 aorta smooth muscle tissue morphogenesis GO:0060414 9.55 MIR145 MIR143
17 positive regulation of corticotropin secretion GO:0051461 9.54 UCN GHRL
18 positive regulation of activated T cell proliferation GO:0042104 9.54 MIR21 MIR155 ICOSLG
19 regulation of phenotypic switching GO:1900239 9.52 MIR145 MIR143
20 gene silencing by miRNA GO:0035195 9.5 MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR145
21 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.46 MIR17 MIR143
22 gastric emptying GO:0035483 9.43 UCN GHRL
23 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.33 MIR199A1 MIR17 MIR155
24 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143
25 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 8.8 MIR199A1 MIR17 MIR155

Molecular functions related to Intestinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR21 MIR199A1 MIR196A1 MIR17 MIR155 MIR145

Sources for Intestinal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....